US regulators have issued a green light for Taro Pharmaceutical Industries’ corticosteroid psoriasis spray.
The group said that the US Food and Drug Administration has approved its application to market Topicort (desoximetasone) Topical Spray for the treatment of plaque psoriasis in patients 18 years of age or older.
Psoriasis is the most prevalent autoimmune disease in the US, affecting as many as 7.5 million – or 2.2% – of the population.
Taro, citing “industry sources”, noted that the corticosteroid spray market in the US is worth around $100 million a year.
